<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6002">
  <stage>Registered</stage>
  <submitdate>26/06/2012</submitdate>
  <approvaldate>26/06/2012</approvaldate>
  <nctid>NCT01633372</nctid>
  <trial_identification>
    <studytitle>An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis</studytitle>
    <scientifictitle>An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>INCB 39110-230</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary Myelofibrosis</healthcondition>
    <healthcondition>Post Polycythemia Vera Fibrosis</healthcondition>
    <healthcondition>Post Essential Thrombocythemia Myelofibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - itacitinib

Experimental: itacitinib (INCB039110) 100 mg - itacitinib (INCB039110) 100 mg twice a day

Experimental: itacitinib (INCB039110) 200 mg - itacitinib (INCB039110) 200 mg twice a day

Experimental: itacitinib (INCB039110) 300 mg - itacitinib (INCB039110) 300 mg once a day

Experimental: itacitinib (INCB039110) 400 mg - itacitinib (INCB039110) 400 mg once a day

Experimental: itacitinib (INCB039110) 600 mg - itacitinib (INCB039110) 600 mg once a day


Treatment: drugs: itacitinib


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects with &gt;/= 50% reduction in total symptom score in each dose group, as measured by the modified The Myelofibrosis Symptom Assessment Form (MFSAF) v3.0 diary</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with &gt;/= 35% reduction in spleen volume, and mean percent change in spleen volume</outcome>
      <timepoint>Baseline, Week 12 and Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of transfusion dependent subjects who exhibit changes in transfusion frequency over any 12 week period on study and proportion of transfusion independent subjects who exhibit changes in hemoglobin level</outcome>
      <timepoint>Baseline to Week 12; Week 13 to Week 24 through the end of study or study termination visit.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of itacitinib (INCB039110) as measured by adverse events.</outcome>
      <timepoint>Every 4-6 weeks through the end of study or early termination visit (approximately 33 weeks exclusive of the extension phase).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must be diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy.

          -  Must score at least 1 point on the Dynamic International Prognostic Scoring System
             (DIPSS) for prognostic risk factors and have peripheral blast count &lt;10% at both
             Screening and Baseline hematology assessments.

          -  Subjects must discontinue all drugs used to treat underlying MF disease no later than
             Day -14.

          -  Subjects must have hemoglobin value &gt;/= 8.0g/dL and be willing to receive blood
             transfusions, have a platelet count &gt;/=50x10^9/L and absolute neutrophil count (ANC)
             &gt;/= 1x10^9/L.

          -  Subjects must have palpable spleen or history of splenectomy

          -  Active symptoms at the screening visit</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women who are pregnant or breastfeeding, and men and women who cannot comply with
             requirements to avoid fathering a child or becoming pregnant, respectively.

          -  Subjects with impaired liver function, end stage renal disease on dialysis or
             clinically significant concurrent infections requiring therapy.

          -  Subjects with unstable cardiac function or invasive malignancies over the previous 2
             years except treated basal or squamous carcinomas of the skin, completely resected
             intraepithelial carcinoma of the cervix and completely resected papillary thyroid and
             follicular thyroid cancers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>125</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital> - Darlinghurst</hospital>
    <hospital> - Kogarah</hospital>
    <hospital> - Box Hill</hospital>
    <hospital> - Frankston</hospital>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Frankston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Incyte Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will
      evaluate safety and efficacy parameters of itacitinib (INCB039110).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01633372</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Albert Assad, MD</name>
      <address>Incyte Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>